Alicia Grande Biography and Net Worth

Vice President, Chief Financial Officer and Treasurer of Catalyst Pharmaceuticals

Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm's Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.

How do I contact Alicia Grande?: The corporate mailing address for Ms. Grande and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Alicia Grande's contact information.
Has Alicia Grande been buying or selling shares of Catalyst Pharmaceuticals?: Alicia Grande has not been actively trading shares of Catalyst Pharmaceuticals in the last ninety days. Learn More on Alicia Grande's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 551,255 shares worth more than $9,231,148.44. The most recent insider tranaction occured on August, 21st when Director David S Tierney sold 15,000 shares worth more than $301,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 8/21/2024.

Alicia Grande Insider Trading History at Catalyst Pharmaceuticals

Alicia Grande Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.48

$21.05

$21.55

50 Day Range

MA: $21.13

$19.56

$23.93

2 Week Range

Now: $21.48

$13.00

$24.27

Volume

863,885 shs

Average Volume

1,086,837 shs

Market Capitalization

$2.56 billion

P/E Ratio

18.20

Dividend Yield

N/A

Beta

0.75

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.